secwatch / observer
8-K filed February 24, 2025, 6:59 PM ET ticker NKTR CIK 0000906709
other material confidence high sentiment positive materiality 0.55

Nektar partners with TrialNet for Phase 2 study of rezpegaldesleukin in type 1 diabetes

NEKTAR THERAPEUTICS

item 8.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001213900-25-016278
form_type
8-K
ticker
NKTR
cik
0000906709
company_name
NEKTAR THERAPEUTICS
filed_at
2025-02-24T23:59:59+00:00
discovered_at
2026-05-14T18:03:06.751419+00:00
generated_at
2026-05-26T06:40:27.507918+00:00
sec_items
["8.01", "9.01"]
event_type
other_material
sentiment
positive
materiality_score
0.55
calibrated_materiality_score
0.55
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001213900-25-016278
json_url
https://secwatch.observer/filing/0001213900-25-016278.json
markdown_url
https://secwatch.observer/filing/0001213900-25-016278.md
text_url
https://secwatch.observer/filing/0001213900-25-016278.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/906709/000121390025016278/0001213900-25-016278-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/906709/000121390025016278/ea0231907-8k_nektar.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Comparable filings

MVIS

MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026

MICROVISION, INC. June 1, 2026, 5:02 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

VDTA

Vertical Data launches Vertical Edge, a direct-ownership edge data center platform

Vertical Data Inc. June 1, 2026, 4:47 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EMYB

Embassy Bancorp expands stock repurchase program by additional $5M

Embassy Bancorp, Inc. June 1, 2026, 4:37 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XAIR

Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026

Beyond Air, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTXR

Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned

Citius Pharmaceuticals, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

SYRE

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ORKA

Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

Oruka Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR
accession 0001213900-25-016278
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.